ClinicalTrials.gg
CompletedNCT01094288Updated Feb 15, 2019Results posted

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

A Phase 1 interventional study of Alisertib and Docetaxel in Advanced Solid Tumors and Adenocarcinoma of the Prostate, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were deemed by the investigator to be medically appropriate candidates for docetaxel therapy.

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have advanced solid tumors including castration-resistant prostate cancer.

The study enrolled approximately 41 patients. Participants were enrolled to receive:

  • Alisertib 10-40 mg + docetaxel 60-75 mg/m\^2

All participants will receive alisertib (ECT) in dose escalating cohorts, orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 [dose held for pharmacokinetic (PK) collection] along with docetaxel 75 mg/m\^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable AEs or withdrawal of consent.

This multi-center trial is conducted in United States. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. Participants made multiple visits to the clinic, and were contacted every 12 weeks for up to 25.8 months after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced Solid Tumors
  • Adenocarcinoma of the Prostate
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  • 18 years or older
  • or cytologically confirmed advanced tumors and candidates for docetaxel treatment
  • Measurable or evaluable disease is required. Participants must have clinical evidence of progressive disease or persistent disease
  • Participants with castration-resistant prostate cancer (CRPC) are required to have

    • Pathologically confirmed adenocarcinoma of the prostate
    • Evidence of disease on bone scan or other imaging. Participants with prostate-specific antigen (PSA) elevation as the only manifestation of disease are not eligible.
    • Progressive disease after at least 1 hormonal treatment with documented testosterone levels less than 50 ng/dl
    • Concurrent use of an agent for testosterone suppression (e.g., luteinizing hormone-releasing hormone [LHRH] agonist) is required if the participants has not been surgically castrated
  • (ECOG) performance status 0-2
  • Recovered to less than or equal to Grade 1 toxicity (), to participant's baseline status (except alopecia) or deemed irreversible from the effects of prior cancer therapy and must have evidence of progressive or persistent disease
  • Adequate bone marrow, liver and renal function
  • Any use of opiates must be stable for at least 2 weeks prior to study entry
  • Female participants who are for at least 1 year OR are surgically sterile OR if of , agree to practice 2 effective methods of at the same time
  • Male participants who agree to practice effective barrier contraception during the entire study and through 6 months after the last dose of study drug OR agree to abstain from heterosexual intercourse
  • Voluntary written consent
  • Willing to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures
  • Suitable venous access for blood sampling

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Female participants who are lactating or pregnant
  • Antineoplastic therapy or any experimental therapy within 21 days before the first dose of alisertib
  • Prior or current therapies within 4 weeks before the first dose of MLN8237
  • Concurrent investigational treatment of treatment with any investigational products within 28 days before the first dose of alisertib
  • Radiotherapy to greater than 40% of bone marrow or any radiotherapy (except localized, small field radiation) within 4 weeks prior to enrollment, unless reviewed and approved by the medical monitor
  • Nitrosoureas or mitomycin-C within 6 weeks before the first dose of alisertib.
  • stem cell transplant within 3 months before the first dose of alisetib, or prior allogeneic stem cell transplant at any time.
  • Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of alisertib
  • For CRPC participants:

    • Radiotherapy or antiandrogen therapy for prostate cancer within 4 weeks prior to enrollment
    • Prior treatment with antineoplastic chemotherapy or radioisotopes for advanced prostate cancer
    • Use of products known to affect PSA levels within 4 weeks of enrollment
  • Major surgery within 4 weeks of study enrollment
  • Uncontrolled high blood pressure
  • Participants with abnormal gastric or bowel function or who require continuous treatment with antacids or proton pump inhibitors
  • Participants receiving chronic therapy other than the following: low dose steroid for the control of nausea and vomiting, topical steroid, inhaled steroid or use of dexamethasone
  • Known severe to docetaxel or other drugs formulated in polysorbate 80
  • Comorbid condition or unresolved toxicity that would preclude administration of docetaxel
  • Prior history of Grade 2 or greater neurotoxicity or any toxicity that has not resolved to Grade 1 or below
  • Symptomatic brain or other
  • Diagnosis or treatment of another within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
  • Known history of (HIV) infection, , or
  • Participants requiring full systemic anticoagulation
  • Prior allogeneic bone marrow or other organ transplant
  • Active infection requiring systemic therapy within 14 days preceding first dose, or other serious infection
  • History of hemorrhagic or thrombotic cerebrovascular event in the past 12 months
  • Serious medical or psychiatric illness that could interfere with protocol completion
  • Inability to swallow oral medication
  • Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
  • Prior treatment with more than 1 prior taxane-containing regimen
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Alisertib + Docetaxel

    Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m\^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent. The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day).

    Drug: Alisertib · Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From enrollment through 30 days after the last dose of study drug (approximately up to 77 months)

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Docetaxel

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2

  2. AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration for Docetaxel

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2

  3. AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity for Docetaxel

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2

  4. Terminal Phase Elimination Half-life (T1/2) for Docetaxel

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2

  5. Cmax: Maximum Observed Plasma Concentration for Alisertib

    Time frame: Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1

  6. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib

    Time frame: Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1

  7. AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Day 7 Over the Dosing Interval for Alisertib

    Time frame: Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1

  8. Overall Response Rate (ORR) Assessed for Overall Participant Population

    ORR is defined as percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by response evaluation criteria in solid tumors (RECIST) v 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in sum of longest diameter (LD) of target lesions in reference to Baseline. RECIST-Evaluable Population is subset of safety population who had measurable disease by RECIST v 1.1 at baseline and had at least 1 post baseline response. prostate specific antigen (PSA)-Evaluable Population is subset of the safety population who had a baseline PSA reference value (\>5 ng/mL) and at least 12 weeks post-baseline PSA assessment for participants with no decline from baseline, or PSA progression within 12 weeks of treatment for participants with PSA decline from baseline.

    Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)

  9. Overall Response Rate for Prostate Cancer Participants

    ORR is defined as percentage of participants who achieved CR or PR as assessed by either RECIST v 1.1 or PSA response by prostate cancer working group 2 (PCWG2) criteria. According to RECIST v 1.1, CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: ≥30% decrease in sum of LD of target lesions in reference to Baseline sum LD. PSA response by PCWG2 is defined as PSA at least 50% decrease in PSA value from baseline for 2 consecutive evaluations. PCWG2 defines PSA progression as the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later.

    Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)

  10. Best Overall Response Rate Assessed by RECIST Criteria

    Best response rate is defined as the percentage of participants with CR, PR, CR+PR, stable disease (SD) and progressive disease (PD) as assessed by RECIST criteria 1.1 for target lesions and assessed by CT, PET or MRI. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)

  11. Best Overall Response Rate Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria

    Best Response Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria PSA response is defined as at least 50% decrease in PSA value from baseline for 2 consecutive evaluations.

    Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)

  12. Duration of Response

    Duration of response is defined as the time from the date of first documentation of a response to the date of first documented progressive disease (PD), or censored at last SD or better.

    Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)

  13. Duration of Stable Disease (SD)

    Duration of SD is defined as the time from first dose to first PD, or censored at last SD or better.

    Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)

07

Results

Posted Feb 15, 2019

Participant flow

Participants took part in the study at 4 investigative sites in the United States from 17 August 2010 to 04 January 2017.

Participant flow — Overall Study
MilestoneAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Started615532424
Completed45112422
Not completed210420002
Withdrew: Adverse event03110000
Withdrew: Withdrawal by subject01200002
Withdrew: Initiation of alternative therapy00100000
Withdrew: Reason not specified23010000
Withdrew: Ongoing participants03000000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From enrollment through 30 days after the last dose of study drug (approximately up to 77 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
AEs615532424
SAEs38321322
SecondaryCmax: Maximum Observed Plasma Concentration for Docetaxel
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
Reported as:
Geometric mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Docetaxel
ng/mLAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Cycle 1 Day 12392.7 ± 60.21730.4 ± 26.51587.0 ± 34.11717.6 ± 51.93751.4 ± 80.81159.9 ± 13.82232.9 ± 19.81386.6 ± 47.0
Cycle 2 Day 11825.1 ± 25.91957.0 ± 23.42146.6 ± 19.43299.9 ± 0.91649.7 ± 19.11061.6 ± 24.82504.6 ± 28.01627.8 ± 17.2
SecondaryAUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration for Docetaxel
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
Reported as:
Geometric mean · hr*ng/mL
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration for Docetaxel
hr*ng/mLAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Cycle 1 Day 12328.3 ± 69.51925.7 ± 21.41750.1 ± 23.12163.4 ± 52.81830.0 ± NA1593.1 ± 14.02394.6 ± 2.71579.8 ± 45.4
Cycle 2 Day 11750.8 ± 23.12416.4 ± 23.725.5 ± 2174.67811.5 ± 87.51622.8 ± 35.01596.0 ± 19.92895.7 ± 16.32510.0 ± NA
SecondaryAUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity for Docetaxel
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
Reported as:
Geometric mean · hr*ng/mL
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity for Docetaxel
hr*ng/mLAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Cycle 1 Day 12653.3 ± 68.12240.6 ± 23.92007.3 ± 15.73570.0 ± NA2130.0 ± NA1734.7 ± 9.62600.0 ± 0.01730.9 ± 53.9
Cycle 2 Day 11918.0 ± 21.42632.2 ± 28.02019.8 ± 10.14000.0 ± NA1785.4 ± 35.61631.0 ± 9.93099.0 ± 14.33120.0 ± NA
SecondaryTerminal Phase Elimination Half-life (T1/2) for Docetaxel
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
Reported as:
Mean · hr
Terminal Phase Elimination Half-life (T1/2) for Docetaxel
hrAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Cycle 1 Day 121.80 ± 4.33922.88 ± 4.73324.00 ± 6.93415.60 ± NA30.70 ± NA16.34 ± 5.68419.25 ± 2.05124.80 ± 6.444
Cycle 2 Day 124.18 ± 2.05020.73 ± 5.84520.40 ± 2.12116.40 ± NA25.10 ± 2.54622.00 ± 2.40416.95 ± 0.63626.00 ± NA
SecondaryCmax: Maximum Observed Plasma Concentration for Alisertib
Time frame:
Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1
Reported as:
Geometric mean · nmol/L
Cmax: Maximum Observed Plasma Concentration for Alisertib
nmol/LAlisertib 10 mgAlisertib 20 mgAlisertib 30 mgAlisertib 40 mg
Cycle 1 Day 1290.4 ± 22.1557.5 ± 57.3751.6 ± 31.31346.4 ± 49.8
Cycle 1 Day 5/Day 7435.8 ± 31.01140.6 ± 44.71637.9 ± 52.11766.3 ± 40.1
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
Time frame:
Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1
Reported as:
Median · hr
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
hrAlisertib 10 mgAlisertib 20 mgAlisertib 30 mgAlisertib 40 mg
Cycle 1 Day 12.050 (2.00 to 3.00)4.000 (2.00 to 9.98)3.560 (2.00 to 12.00)1.500 (1.00 to 7.58)
Cycle 1 Day 5/Day 73.510 (1.87 to 8.22)3.030 (2.00 to 9.40)2.030 (2.00 to 8.00)1.975 (1.08 to 3.00)
SecondaryAUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Day 7 Over the Dosing Interval for Alisertib
Time frame:
Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1
Reported as:
Geometric mean · hr*nmol/L
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Day 7 Over the Dosing Interval for Alisertib
hr*nmol/LAlisertib 10 mgAlisertib 20 mgAlisertib 30 mgAlisertib 40 mg
Cycle 1 Day 11635.0 ± 28.33303.0 ± 46.14387.5 ± 30.18013.7 ± 43.1
Cycle 1 Day 5/Day 73052.8 ± 42.08546.0 ± 49.713199.1 ± 60.812630.0 ± 27.7
SecondaryOverall Response Rate (ORR) Assessed for Overall Participant Population

ORR is defined as percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by response evaluation criteria in solid tumors (RECIST) v 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in sum of longest diameter (LD) of target lesions in reference to Baseline. RECIST-Evaluable Population is subset of safety population who had measurable disease by RECIST v 1.1 at baseline and had at least 1 post baseline response. prostate specific antigen (PSA)-Evaluable Population is subset of the safety population who had a baseline PSA reference value (\>5 ng/mL) and at least 12 weeks post-baseline PSA assessment for participants with no decline from baseline, or PSA progression within 12 weeks of treatment for participants with PSA decline from baseline.

Time frame:
Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Assessed for Overall Participant Population
percentage of participantsAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Overall Response Rate (ORR) Assessed for Overall Participant Population50 (12 to 88)10 (0 to 45)100 (NA to NA)50 (1 to 99)0 (0 to 0)25 (1 to 81)0 (0 to 0)50 (1 to 99)
SecondaryOverall Response Rate for Prostate Cancer Participants

ORR is defined as percentage of participants who achieved CR or PR as assessed by either RECIST v 1.1 or PSA response by prostate cancer working group 2 (PCWG2) criteria. According to RECIST v 1.1, CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: ≥30% decrease in sum of LD of target lesions in reference to Baseline sum LD. PSA response by PCWG2 is defined as PSA at least 50% decrease in PSA value from baseline for 2 consecutive evaluations. PCWG2 defines PSA progression as the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later.

Time frame:
Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Reported as:
Number · percentage of participants
Overall Response Rate for Prostate Cancer Participants
percentage of participantsAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Overall Response Rate for Prostate Cancer Participants50 (12 to 88)20 (1 to 72)—100 (NA to NA)—0 (0 to 0)—100 (NA to NA)
SecondaryBest Overall Response Rate Assessed by RECIST Criteria

Best response rate is defined as the percentage of participants with CR, PR, CR+PR, stable disease (SD) and progressive disease (PD) as assessed by RECIST criteria 1.1 for target lesions and assessed by CT, PET or MRI. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Reported as:
Number · percentage of participants
Best Overall Response Rate Assessed by RECIST Criteria
percentage of participantsAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Complete Response (CR)0 (0 to 0)0 (0 to 0)100 (NA to NA)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
Partial Response (PR)50 (12 to 88)11 (0 to 48)0 (0 to 0)50 (1 to 99)0 (0 to 0)25 (1 to 81)0 (0 to 0)50 (1 to 99)
CR+PR50 (12 to 88)11 (0 to 48)100 (NA to NA)50 (1 to 99)0 (0 to 0)25 (1 to 81)0 (0 to 0)50 (1 to 99)
Stable Disease (SD)50 (12 to 88)67 (30 to 93)0 (0 to 0)0 (0 to 0)50 (1 to 99)0 (0 to 0)0 (0 to 0)50 (1 to 99)
Progressive Disease (PD)0 (0 to 0)22 (3 to 60)0 (0 to 0)50 (1 to 99)50 (1 to 99)75 (19 to 99)100 (NA to NA)0 (0 to 0)
SecondaryBest Overall Response Rate Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria

Best Response Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria PSA response is defined as at least 50% decrease in PSA value from baseline for 2 consecutive evaluations.

Time frame:
Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Reported as:
Number · percentage of participants
Best Overall Response Rate Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria
percentage of participantsAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
≥50% Reduction from Baseline67 (22 to 96)80 (28 to 99)—100 (NA to NA)————
<50% Reduction from Baseline33 (4 to 78)20 (1 to 72)—0 (0 to 0)————
SecondaryDuration of Response

Duration of response is defined as the time from the date of first documentation of a response to the date of first documented progressive disease (PD), or censored at last SD or better.

Time frame:
Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Reported as:
Median · days
Duration of Response
daysAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Duration of Response187 (43 to 187)342 (342 to 342)830 (830 to 830)176 (176 to 176)—79 (79 to 79)—NA (1 to 1)
SecondaryDuration of Stable Disease (SD)

Duration of SD is defined as the time from first dose to first PD, or censored at last SD or better.

Time frame:
Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Reported as:
Median · days
Duration of Stable Disease (SD)
daysAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Duration of Stable Disease (SD)253 (85 to 253)NA (169 to 751)——309 (309 to 309)——134 (134 to 134)

Adverse events

Collected over From signing of the informed consent form up to 30 days after the last dose of study drug (up to 25.8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2—3/6 (50%)6/6 (100%)
Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2—10/15 (66.7%)14/15 (93.3%)
Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2—3/5 (60%)5/5 (100%)
Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2—2/3 (66.7%)3/3 (100%)
Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2—1/2 (50%)2/2 (100%)
Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2—3/4 (75%)4/4 (100%)
Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF—2/2 (100%)2/2 (100%)
Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF—2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
Febrile neutropeniaBlood and lymphatic system disorders1/66/151/51/31/21/40/21/4
AnaemiaBlood and lymphatic system disorders0/61/150/50/30/20/41/20/4
Urinary tract infectionInfections and infestations0/61/151/50/30/20/41/20/4
Clostridium difficile colitisInfections and infestations0/60/150/50/30/21/41/20/4
PneumoniaInfections and infestations0/60/150/51/30/20/41/20/4
DehydrationMetabolism and nutrition disorders0/60/150/50/30/21/41/20/4
StomatitisGastrointestinal disorders0/61/151/51/30/20/40/20/4
ConstipationGastrointestinal disorders0/60/150/51/30/20/40/20/4
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/150/51/30/20/40/20/4
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/150/51/30/20/40/20/4
Most frequent other events
Showing 10 of 219
Most frequent other events
EventAlisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF
StomatitisGastrointestinal disorders1/69/152/51/30/21/41/24/4
NeutropeniaBlood and lymphatic system disorders6/69/155/53/32/24/42/22/4
AnaemiaBlood and lymphatic system disorders2/66/153/53/31/23/41/21/4
LeukopeniaBlood and lymphatic system disorders1/64/152/51/31/22/42/21/4
FatigueGeneral disorders3/610/154/51/32/21/42/22/4
DysgeusiaNervous system disorders4/65/153/51/32/20/40/22/4
Peripheral sensory neuropathyNervous system disorders3/65/150/50/32/20/40/20/4
AlopeciaSkin and subcutaneous tissue disorders3/67/153/51/32/21/41/22/4
Rash pruriticSkin and subcutaneous tissue disorders0/62/150/50/30/20/42/20/4
DehydrationMetabolism and nutrition disorders0/65/151/50/30/21/42/21/4

Baseline characteristics

Safety Population included all participants who received at least 1 dose of any study drug.

Age, Continuous
Age, Continuous(years)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
Mean63.7 ± 5.2061.5 ± 13.1060.2 ± 16.7561.3 ± 8.6256.5 ± 2.1254.8 ± 18.7352.5 ± 26.1662.3 ± 25.7160.4 ± 14.07
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
Female0411112111
Male61142130330
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
Hispanic or Latino050001107
Not Hispanic or Latino61053131433
Not Reported000010001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
White61552232338
Black or African American000001012
Other000100001
Region of Enrollment
Region of Enrollment(participants)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
United States61553242441
Height
Height(cm)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
Mean185.5 ± 11.02170.5 ± 10.04177.2 ± 12.13171.0 ± 10.08174.5 ± 0.71172.5 ± 10.98155.6 ± 8.08174.9 ± 6.99173.6 ± 11.32
Weight
Weight(kg)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
Mean100.25 ± 15.84282.73 ± 16.96394.15 ± 25.62387.73 ± 31.98776.90 ± 8.34485.97 ± 15.98762.05 ± 11.95087.05 ± 21.02586.50 ± 19.550
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSFAlisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSFTotal
Mean2.269 ± 0.23291.973 ± 0.25332.138 ± 0.35412.025 ± 0.43161.929 ± 0.10092.026 ± 0.24201.635 ± 0.20052.046 ± 0.29452.034 ± 0.2878
08

Study locations

4 sites
  • Indianapolis, Indiana, United States
  • Portland, Oregon, United States
  • San Antonio, Texas, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2010 to primary completion in Feb 2014, 42 months.

Results were first posted in Feb 2019, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2010
First posted
Mar 26, 2010
StartActual
Aug 17, 2010
Primary completionActual
Feb 28, 2014
CompletionActual
Jan 4, 2017
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01094288
Responsible party
Sponsor
First posted
Mar 26, 2010
Start date
Aug 17, 2010
Primary completion
Feb 28, 2014
Completion
Jan 4, 2017
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion